Acceptability and feasibility of S-1 plus cisplatin adjuvant chemotherapy for completely resected non-small cell lung cancer: an open-label, single arm, multicenter, phase 2 trial

BACKGROUND: Although platinum-based chemotherapy is accepted as adjuvant chemotherapy for resectable advanced non-small cell lung cancer (NSCLC), its completion rate is low due to severe adverse events. S-1 plus cisplatin is associated with relatively low toxicity and an unimpaired quality of life,...

Descripción completa

Detalles Bibliográficos
Autores principales: Uematsu, Shugo, Sano, Atsushi, Isobe, Kazutoshi, Usui, Kazuhiro, Matsumoto, Jun, Kiribayashi, Takaharu, Obara, Kiyohaya, Kitami, Akihiko, Murakami, Yoshitaka, Iyoda, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107543/
https://www.ncbi.nlm.nih.gov/pubmed/34012573
http://dx.doi.org/10.21037/jtd-20-3293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107543/
https://www.ncbi.nlm.nih.gov/pubmed/34012573
http://dx.doi.org/10.21037/jtd-20-3293

Ejemplares similares